CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare ...
Findings showed 28.1% of patients treated with mitapivat achieved a TRR vs 11.8% of patients who received placebo. A phase 3 trial evaluating mitapivat in pediatric patients with pyruvate kinase ...
Agios Pharmaceuticals announced that it will present new data on its pyruvate kinase activators, mitapivat and tebapivat, during the 30th European Hematology Association (EHA) Congress in Milan from ...
Tumor M2 Pyruvate Kinase: A Tumor Marker and its Clinical Application in Gastrointestinal Malignancy
Proliferating cells, in particular tumor cells, express a dimeric isoenzyme of pyruvate kinase, termed Tumor M2 pyruvate kinase. In the last few years, much attention has been paid to this novel tumor ...
EXTON, PA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- According to the latest findings from Spherix Global Insights’ syndicated Market Dynamix™ service, the US sickle cell disease (SCD) market is approaching a ...
Agios Pharmaceuticals has announced that the European Commission has granted orphan medicinal product designation to mitapivat, an oral small molecule pyruvate kinase (PK) activator, for the treatment ...
EXTON, PA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- According to the latest findings from Spherix Global Insights’ syndicated Market Dynamix™ service, the US sickle cell disease (SCD) market is approaching a ...
Non-small-cell lung cancer (NSCLC) accounts for up to 85% of all cases of lung cancer, which is the most frequent cause of cancer-related deaths worldwide. The need for effective treatments against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback